.Attributes Medication, Released online: 03 September 2024 doi:10.1038/ s41591-024-03223-zThis Perspective requires inclusion of patients with MASLD and also measurement of liver end results in cardio-- renal-- metabolic trials, when records recommend mechanistically probable perks and professional protection-- and lays out factors for trial concept as well as regulative commendation.